Sign in

You're signed outSign in or to get full access.

Ellen Havdala

Director at Ardent Health
Board

About Ellen Havdala

Independent director since January 2019; age 59 as of April 1, 2025. Managing Director at Equity Group Investments (EGI) with three decades of investment and portfolio company oversight experience; prior roles include executive positions at Equity International and Scott Sports Group, and early career as a financial analyst at First Boston. Education: BA in Economics magna cum laude from Harvard College; Master of Divinity from the University of Chicago (2016). Board nominated under the Nomination Agreement as an EGI-AM designee; Board determined she is independent under NYSE rules despite EGI affiliations .

Past Roles

OrganizationRoleTenureCommittees/Impact
Equity Group Investments (EGI)Managing DirectorSince joining EGI affiliates in Sep 1990; current MDRepresents EGI in sourcing/evaluating investments and portfolio work; oversees Zell Global Entrepreneurship Network
Equity InternationalExecutive Vice PresidentPrior role (dates not specified)Executive leadership role at EGI affiliate
Scott Sports Group, Inc.Vice PresidentPrior role (dates not specified)Executive role
The First Boston CorporationFinancial Analyst1988 (early career)Investment banking analysis experience

External Roles

OrganizationRoleStartType
CraneWorks, Inc.DirectorApr 2024Private company board
Zell Lurie Institute, Univ. of Michigan RossBoard MemberOngoingAcademic/Non-profit board
Zell Global Entrepreneurship NetworkEstablish/OverseeOngoingProgram leadership and mentorship network oversight
Prior boards (selected)DirectorVariousLanter Delivery Systems; Equity Distribution Acquisition Corp.; SIRVA, Inc.; Rewards Network; WRS Holding Company; East Mediterranean Gas Company SAE; National Patent Development Corp.; Home Products International

Board Governance

  • Committees and roles: Chair, Compensation Committee; member, Patient Safety and Quality of Care Committee. Compensation Committee met nine times in 2024; Quality Committee met four times .
  • Independence: Board concluded Havdala qualifies as independent under NYSE rules despite EGI-AM’s controlling stake and service agreements; ARDT is a “controlled company” and not required to have a majority-independent Board or fully independent Compensation Committee .
  • Attendance: Board held six meetings in 2024; each director, including Havdala, attended at least 75% of Board and committee meetings on which they served .
  • Executive sessions: Each regular Board meeting includes an executive session of non-employee directors; independent directors meet in executive session at least annually .

Fixed Compensation

Component2024 AmountNotes
Annual Board cash retainer$100,000Under 2024 non-employee director program adopted at IPO
Committee retainers (policy)Chair: Compensation $20,000; Member: Audit $15,000; Compensation $10,000; Nominating $7,500; Quality $10,000Policy schedule; Havdala is Compensation Chair and Quality member
Fees earned in cash (actual)$107,5002024 actual cash received (reflects proration post-IPO and committee roles)

Performance Compensation

Equity AwardGrant/OutstandingGrant Date ValueVesting
Annual Director RSUs22,355 RSUs outstanding at 12/31/2024$185,000 per standard annual grant; Havdala total 2024 stock awards $365,235 (includes Special Director RSUs)Annual RSUs generally vest over 12 months; 2024 Annual Director RSUs vest March 31, 2025
Special Director RSUsIncluded in $365,235Granted Dec 2024 for retention; not granted to Sotir/SenVest in three equal installments on Dec 12, 2025/2026/2027; accelerated upon Change in Control

Director equity is time-based RSUs; no performance metrics (TSR/financial) apply to directors under the 2024 program .

Other Directorships & Interlocks

  • EGI-AM and Ventas nomination rights: EGI-AM can nominate a majority of directors and designate the Chairman while >50% voting power; Ventas (via ALH Holdings) nominates one director while it and affiliates hold ≥4% voting power .
  • Services Agreement with EGI-AM providing advisory services and information/access rights (no fee; reimbursable expenses; indemnification), representing a related-party framework considered in independence determinations .

Expertise & Qualifications

  • Deep private equity and portfolio company oversight; governance and compensation leadership as Compensation Committee Chair .
  • Healthcare services Board exposure through ARDT’s Quality Committee; enhances oversight of patient safety and care quality policies .
  • Academic and entrepreneurship program governance (Zell Lurie Institute; Zell Global Entrepreneurship Network) .

Equity Ownership

HolderShares Beneficially Owned% of ClassComponents/Notes
Ellen Havdala77,427<1%Includes 11,562 RSUs vesting within 60 days of 3/28/2025 (counted as beneficial for SEC purposes)
RSUs outstanding (dir. program)22,355n/aRSUs outstanding as of 12/31/2024
Ownership guideline5x annual cash retainern/aAs of 12/31/2024, all non-employee directors except Sotir and Sen exceeded guideline; implies Havdala meets guideline

Insider Trades (Form 4)

Filing DateSummaryKey Terms
Dec 16, 2024Reported grant of RSUs pursuant to director equity program; footnote indicates RSUs vest in three equal installmentsRSUs vest over three years; transaction reflects director compensation awards
Mar 25, 2025Reported RSUs; footnote references vesting “on the first anniversary of March 21, 2025” (award-specific)RSUs time-based vesting; Form shows current beneficial ownership after transactions

No pledging/hedging disclosures identified in these Form 4 filings; ARDT’s insider trading policy governs director transactions .

Governance Assessment

  • Strengths

    • Independent status affirmed despite EGI affiliation; active leadership as Compensation Committee Chair and member of Quality Committee demonstrates engaged governance .
    • Strong shareholder support in 2025: Say-on-Pay received 101,457,024 For vs 1,202,587 Against; frequency vote supported annual say-on-pay (102,656,561 votes) .
    • Compensation Committee exercised negative discretion to normalize NEO bonuses to 100% despite formulaic >140% outcome due to unplanned New Mexico program approval—evidence of pay discipline under Havdala’s chairmanship .
    • Director equity ownership meets/exceeds guidelines, aligning incentives with shareholders .
  • Risks and RED FLAGS

    • Controlled company governance: EGI-AM holds >50% voting power; EGI-AM designees comprise a majority of Compensation and Nominating Committees; Havdala is an EGI Managing Director—monitor for potential influence over pay and nominations despite independence conclusion .
    • Related-party framework: EGI-AM Services Agreement (advisory/information rights; expense reimbursement; indemnification). While Board deemed independence intact, the structure warrants ongoing scrutiny for conflicts .
    • Committee independence: As a controlled company, Compensation Committee need not be solely independent under NYSE rules. Continued transparency on advisor independence (WTW) and committee processes mitigates risk .

2025 Annual Meeting Results — Ellen Havdala

ItemForWithholdBroker Non-Votes
Director Election (Havdala)96,271,1646,694,6164,800,840

Director Compensation (Detail)

Metric2024
Fees Earned or Paid in Cash$107,500
Stock Awards (RSUs)$365,235
Total$472,735
RSUs Outstanding (12/31/2024)22,355
Annual Cash Retainer (Policy)$100,000
Compensation Committee Chair Fee (Policy)$20,000
Quality Committee Member Fee (Policy)$10,000
Director Equity Vesting (2024 grants)Annual RSUs vest Mar 31, 2025; Special Director RSUs vest Dec 12, 2025/2026/2027

Related Party & Conflicts

  • EGI-AM Nomination Agreement grants majority nomination rights; Ventas nominates one director while ≥4% ownership; Havdala designated by EGI-AM .
  • EGI-AM Services Agreement provides advisory services and information/access rights; no fee but reimbursable expenses and indemnification; Board considered this in independence determinations .
  • No specific transactions disclosed involving Havdala personally in the “Certain Relationships and Related Party Transactions” section; Audit & Compliance Committee reviews related-person transactions .

Compensation Committee Analysis

  • Committee composition: Havdala (Chair), Bynoe, Bulgarelli, Campion, Sen; nine meetings in 2024 .
  • Consultant: Willis Towers Watson (WTW) engaged; Committee determined no conflicts of interest; WTW provided compensation design and benchmarking; 2024 fees to WTW and affiliates disclosed ($542,841 executive comp consulting; $2,418,694 benefits administration) .
  • Committee responsibilities include director pay structure and equity plan administration; EGI-AM designees comprise a majority while EGI-AM >50% voting power per Nomination Agreement .

Equity Ownership & Alignment Policy

  • Stock Ownership Guidelines: Non-employee directors must hold shares equal to 5x annual cash retainer; compliance required within 5 years of IPO (by July 18, 2029); Havdala meets guideline; Sotir and Sen not yet at guideline as of 12/31/2024 .

Employment & Contracts (director-specific)

  • Director compensation program: post-IPO 2024 Program instituted with cash retainers and time-based RSUs; vesting accelerates upon Change in Control; proration for partial-year service .

Performance & Track Record

  • As Compensation Chair, Havdala presided over the decision to cap 2024 Corporate Executive Bonus Plan payouts at 100% of target despite formulaic outcome >140%—a shareholder-friendly governance action .
  • Strong director election support and say-on-pay approval indicate investor confidence in current governance .

Governance Signals Summary

  • Positive: Independence affirmations; active committee leadership; disciplined pay decisions; strong say-on-pay and election outcomes; ownership guideline compliance .
  • Monitor: Controlled company dynamics; EGI-AM advisory and nomination rights; ensure continued transparency and rigorous oversight to mitigate potential conflicts .